Please search for your last name

no photo
Ente Ospedaliero Cantonale (EOC)
Neurocenter of Southern Switzerland
no photo
Qatar Biomedical research Institute
Neurological Disorders Research Center
no photo
Institut de Pharmacologie Moléculaire et Cellulaire/CNRS
UMR7275
no photo
no photo
1V.M. Bekhterev National Medical Research Center of Psychiatry and Neurology
Centre of Personalized Psychiatry and Neurology
no photo
Shahid Beheshti University of Medical Sciences
Neuroscience Research center
Amsterdam UMC
Amsterdam Neuroscience - Industry Alliance office
Pieter van Bokhoven is the Chief Scientific Officer and head of the Industry Alliance Office of Amsterdam Neuroscience, Amsterdam UMC. Pieter obtained his PhD in molecular neuroscience in 2011 at the VU University Amsterdam, focusing his research on the molecular underpinning of learning and memory. He published high-impact papers on the topic. He broadened his business experience as an entrepreneur as founding partner of an SME developing applications for pharmaceutical companies. In his current role Pieter is responsible for initiating research projects for drug development and diagnostics for neurodegeneration. This is always in collaboration with industry partners from biotech and pharma and translational in nature. His focus is on bringing new interventions from the lab to patients at Amsterdam UMC, in early clinical development. Pieter has profound knowledge of molecular targets for drugs for Alzheimer’s disease, novel treatment methods and therapeutic modalities, and companion diagnostics.
University of Antwerp
Biomedical Sciences
Christine Van Broeckhoven obtained her master’s degree in 1975 in Chemistry, with a minor in Biochemistry, from the University of Antwerp, and her PhD in Molecular Biology in 1980. From 1979 to 1988, she did postdoctoral research on metabolic diseases at the Antwerp Institute for Hygiene. In 1983 she started her own lab on neurogenetics of neurodegenerative diseases at the University of Antwerp. In 1994, she obtained the Doctor in Science degree based on her Molecular Genetics research into Alzheimer’s disease. In 1996, she was a Distinguished Alzheimer Professor at the University of Leiden in The Netherlands, and in 2001 she was a Guest Scientist in the Scripps Research Institute, San Diego, USA. Today, she is best known for her pioneering research into brain diseases in which she made several seminal contributions. Her work to unravel the genetic basis of neurodegenerative dementia and psychiatric diseases has been awarded several times by numerous national and international awards including the prestigious Potamkin Prize by the American Academy of Neurology (1993); the Belgian Excellence Prize Joseph Maisin (1995); the International L’Oréal/UNESCO Women in Science Award (2006) Paris France; the European Inventor Award for Research (2011); the America MetLife Foundation Award for Medical Research (2012) New York and recent the Khalid Iqbal Lifetime Achievement Award in Alzheimer’s Disease Research of the Alzheimer’s Association (2020) Chicago. She is Member of the Royal Flemish Academy of Belgium for Sciences and the Arts (199). For her societal engagements she is honored by the Belgian title of Royal Grand Officer in the Order of Leopold (2006) and the French Order of Chevalier dans La Légion d’Honneur (2008).
Amsterdam UMC, Vrije Universiteit Amsterdam
Department of Anatomy and Neurosciences
Wilma van de Berg is senior neuroscientist, principal investigator, associate professsor at dept. Anatomy and Neurosciences, head of the research section Clinical Neuroanatomy and Biobanking (CNAB). She is founder and director of the Normal Aging Brain Collection (www.nabca.eu), which collects advanced postmortem MRI and high-quality brain tissue of non-demented elderly for stimulating translational research in neurosciences. Wilma van de Berg is an expert in human neuroanatomy, neuropathology and morphometry of Parkinson's disease. She has a strong interest in translating knowledge on pathogenesis in Parkinson's diseasse in novel (progression) biomarkers and developing new disease-modifying treatment strategies aiming to slow down or halt Parkinson’s disease progression. Her research team studies human brain morphology, neuropathological lesions and molecular mechanisms underlying alpha-synuclein aggregation in postmortem brain tissue of aged individuals and patients with Parkinson’s disease, Dementia with Lewy bodies and Alzheimer’s disease from macro-to-nanoscale using advanced MRI, correlative microscopic imaging and multi-omics methods. Wilma van de Berg has experience in conducting clinical studies (e.g. PROGRES-PD) in which Parkinson patients were followed for eight years to study relationship between biofluid markers and cognitive decline in PD. In close collaboration with acadmic and industry partners, she setup a large multicenter longitudinal observational study ‘Profiling Parkinson’s disease’ (ProPARK) to identify molecular profiles underlying disease severity, progression and adverse drug reactions and translate this knowledge into biomarker panels for next clinical trials.
Radboud University Medical Center
Neurology
PhD candidate at the Radboud University Medical Center focused on cellular mechanisms and molecular biomarkers of cerebral amyloid angiopathy.
no photo
Amsterdam UMC, location VUmc
Anatomy and Neurosciences, section Clinical Neuroanatomy and Biobanking
Amsterdam UMC
Human genetics, section Genomics of Neurodegeneration and Aging
Sven van der Lee, graduated from Medical school in 2012 and after a schort internship in Neurology focussed on research. He has a PhD in genetic epidemiology of Alzheimers disease and related traits (2017) at the Erasmus Medical center. He continued working on translating genetic findings into the clinical care at the Amsterdam UMC at the human genetics department in close collaboration with the Amsterdam Alzheimer Center.
University of Groningen
Department of clinical and developmental neuropsychology
I. (Iris) van der Lijn, neuropsychologist at Royal Dutch Visio and PhD-student at the University of Groningen (RUG). Research project NAH-Progress: Care for people with Parkinson’s disease is improving. However, visual complaints and disorders often go neglected, and visual rehabilitation is not always applied. NAH-Progress, a project financially supported by Stichting Novum and ZonMw Expertisefunctie Zintuiglijk Gehandicapten, aims at organizing high-quality chain-based care. In 2016, the Parkinson Expertise Center in Groningen and Royal Dutch Visio started collaborating. The collaboration concerns systematic screening, referral routes and scientific research. Patients are screened for visual complaints and if necessary referred to Royal Dutch Visio. Royal Dutch Visio has the knowledge and expertise to provide high-quality visual care and rehabilitation. Data yielded during the screening and visual rehabilitation process are collected and analyzed to better understand the visual problems people with Parkinson’s disease may experience.
no photo
University Hospital Cologne and Medical Faculty of the University of Cologne
Multimodal Imaging Group, Department of Nuclear Medicine
no photo
University of Kentucky
Neurosurgery
University Medical Centre Groningen
Department of Neurology
Professor Teus van Laar is Medical Director of the Parkinson Expertise Center at the University of Groningen in Groningen, the Netherlands, where his team treats 1500 patients with PD, and offers all advanced therapies. He is a clinical neurologist and pharmacologist with expertise in movement disorders, especially Parkinson’s disease (PD), and the effect of pharmacological interventions on this disease. In 2010, he started the Parkinson Platform Northern Netherlands, which is a regional platform of 13 hospitals, which was the start of many clinical and research collaborations focusing especially on the pathophysiology and subtyping of PD, in order to develop personalized treatments for PD patients. In 2017 he started the DUPARC cohort, a de novo PD cohort with extensive pheno- and genotyping of over 150 participants, including imaging, clinical assessments of motor- and non-motor symptoms, OCT (optical coherent tomography) and microbiome analysis. He is reviewer of several neurological and neuroscience journals and is member of the board of the Dutch Parkinson Scientists.
Epilog NV
Technical Operations
Prof. Pieter van Mierlo obtained his Ph.D. in biomedical engineering at Ghent University in 2013 for his research on the localization of the epileptogenic focus using EEG-derived functional brain networks. After a post-doctoral fellowship at Geneva University, Pieter van Mierlo became assistant professor at Ghent University in 2018, where he currently leads the neuro-engineering lab. The main research topics are EEG source imaging, functional brain connectivity and EEG biomarkers to study neurological disorders. Prof. van Mierlo is co-founder and CTO of the spin-off company Epilog that provides EEG insight for better patient care.
Amsterdam UMC
Molecular Cell Biology & Immunology
I currently work as a PhD student studying (neuro)immunological processes that underlie Alzheimer's disease, MS and aging at prof. HE de Vries' lab at the Department of Molecular Cell Biology and Immunology in the Amsterdam UMC. From June 2022 onwards, I'll be working as a post-doc in the Gate lab @ Northwestern University in Chicago.
no photo
NeuroVision Imaging, Inc
Biomarker Development
no photo
Fujirebio
R&D Product Development